We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The last step to achieve barrier damage control.
- Authors
Baglivo, Ilaria; Colantuono, Stefania; Lumaca, Arianna; Papa, Alfredo; Gasbarrini, Antonio; Caruso, Cristiano
- Abstract
Heterogeneity characterises inflammatory diseases and different phenotypes and endotypes have been identified. Both innate and adaptive immunity contribute to the immunopathological mechanism of these diseases and barrier damage plays a prominent role triggering type 2 inflammation through the alarmins system, such as anti-Thymic Stromal Lymphopoietin (TSLP). Treatment with anti-TSLP monoclonal antibodies showed efficacy in severe asthma and clinical trials for other eosinophilic diseases are ongoing. The aim of this perspective review is to analyse current advances and future applications of TSLP inhibition to control barrier damage.
- Subjects
NATURAL immunity; MONOCLONAL antibodies; THYMIC stromal lymphopoietin; CLINICAL trials
- Publication
Frontiers in Immunology, 2024, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2024.1354556